Josephin Domain Containing 2 (JOSD2) inhibition as Pan-KRAS-mutation-targeting strategy for colorectal cancer
Abstract KRAS is the most common mutated oncogenes in caruso rhodiola colorectal cancer (CRC), yet effective therapeutic strategies for targeting multiple KRAS mutations remained challenging.The prolonged protein stability of KRAS mutants contribute to their robust tumor-promoting effects, but the underlying mechanism is elusive.Herein by screening